PALI vs SPTX
PALI: A clinical-stage biotech developing PALI-2108, a licensed small-molecule candidate in Phase 1 trials, with a capital-dependent model dependent on licensing agreements and third-party manufacturing. SPTX: Seaport Therapeutics is a clinical-stage biopharmaceutical company advancing a pipeline of novel therapeutics using its proprietary drug development platform.
Side-by-side fundamentals
| Metric | PALI | SPTX | Edge |
|---|---|---|---|
| Price as of 2026-07-22 close | $1.90 | $21.30 | |
| Market cap as of 2026-07-23 | $331M | $1.1B | |
| Net margin as of 2026-07-23 | -936.0% | n/a | |
| Operating margin as of 2026-07-23 | -1011.6% | n/a | |
| ROE as of 2026-07-23 | -36.8% | -24.2% | SPTX higher |
| ROA as of 2026-07-23 | -34.3% | -22.6% | SPTX higher |
| Debt / equity as of 2026-07-23 | 0.00 | 0.00 | Tie |
| Beta as of 2026-07-23 | 1.46 | -1.38 | |
| 1-year return as of 2026-07-22 close | +120.9% | +5.8% | PALI higher |
Fundamentals: Finnhub, as of 2026-07-23. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-22.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.